Study of hydatidiform mole after first diagnosis
Part of Cancer, Women’s health & pregnancy clinical trials.
This study follows people who have been newly diagnosed with a hydatidiform mole (an abnormal pregnancy tissue growth). It aims to learn more about the condition using information from clinical evaluation and tissue testing, which may improve understanding and care in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new (first-time) diagnosis of hydatidiform mole
- Your age is between 13 and 55 years
- You can sign a consent form to join the study
- You have a pathology (tissue) diagnosis to confirm the type
- You do not have another type of cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people diagnosed with a hydatidiform mole (a rare pregnancy-related tumor) to understand how it progresses. It follows your health after the mole is removed and checks your hCG levels (a pregnancy hormone) to see if you develop a related condition called post-molar gestational trophoblastic neoplasia.
This study looks at different treatment approaches for hydatidiform mole when a CT scan shows lung nodules and the team cannot rule out spread. It may help guide the safest next steps and follow-up plan.
This study is for people who have a pregnancy-related tumor called gestational trophoblastic disease. It looks at this condition in patients who were diagnosed by blood test (hCG) changes or tissue testing, to better understand and manage the disease.
This study uses ultrasound to check blood flow in the uterus after removing a complete hydatidiform mole, to predict the risk of developing persistent gestational trophoblastic neoplasia (a type of tumor). The goal is to identify patients who may need closer monitoring or earlier treatment.
This study follows women who are newly diagnosed with cervical or endometrial (uterine lining) cancer at a health check-up. It helps doctors learn more about these cancers and how they behave, which may improve future care.
This trial tests if an immunotherapy drug (anti-PD1) can change atypical (dysplastic) moles in people who have had melanoma. It may help understand how these drugs affect mole cells.
Hear when a new Hydatidiform Mole trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.